GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Cyclically Adjusted Price-to-FCF

Hikma Pharmaceuticals (LSE:HIK) Cyclically Adjusted Price-to-FCF : 16.86 (As of May. 21, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Cyclically Adjusted Price-to-FCF?

As of today (2024-05-21), Hikma Pharmaceuticals's current share price is £19.73. Hikma Pharmaceuticals's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 was £1.17. Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 16.86.

The historical rank and industry rank for Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LSE:HIK' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.76   Med: 33.52   Max: 121
Current: 16.85

During the past 13 years, Hikma Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 121.00. The lowest was 13.76. And the median was 33.52.

LSE:HIK's Cyclically Adjusted Price-to-FCF is ranked better than
76.22% of 328 companies
in the Drug Manufacturers industry
Industry Median: 33.51 vs LSE:HIK: 16.85

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Hikma Pharmaceuticals's adjusted free cash flow per share data of for the fiscal year that ended in Dec23 was £1.894. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is £1.17 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Hikma Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.36 34.71 25.40 14.82 15.24

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.40 - 14.82 - 15.24

Competitive Comparison of Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Hikma Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=19.73/1.17
=16.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Hikma Pharmaceuticals's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=1.894/130.5000*130.5000
=1.894

Current CPI (Dec23) = 130.5000.

Hikma Pharmaceuticals Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.981 99.900 1.281
201512 0.761 100.400 0.989
201612 0.353 102.200 0.451
201712 0.904 105.000 1.124
201812 0.950 107.100 1.158
201912 0.898 108.500 1.080
202012 0.750 109.400 0.895
202112 1.320 114.700 1.502
202212 1.314 125.300 1.369
202312 1.894 130.500 1.894

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hikma Pharmaceuticals  (LSE:HIK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Hikma Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (LSE:HIK) Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines